Johnson & Johnson announced that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire effective September 1, 2026. She will be succeeded by Tom Cavanaugh, who currently serves as Company Group Chairman, North America, Innovative Medicine. Under Taubert's leadership, the Innovative Medicine business grew to over $60 billion in annual revenue.
Key Details
- Departing Executive: Jennifer Taubert will retire from her role as EVP, Worldwide Chairman, Innovative Medicine and member of the Executive Committee.
- Successor: Tom Cavanaugh has been appointed to succeed Ms. Taubert and will join the Johnson & Johnson Executive Committee.
- Effective Date: The leadership transition is effective September 1, 2026.